Howard Belmont

Professor (Clinical) of Medicine

NYU School of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Howard Belmont is a Professor (Clinical) of Medicine at NYU School of Medicine in the United States. His research primarily focuses on systemic lupus erythematosus, with recent articles addressing topics such as the evaluation of glucagon-like peptide-1 receptor agonists in lupus patients and the impact of autoantibody concentrations on lupus nephritis. He also investigates the quality of life associated with extrarenal symptoms and the epidemiology of mixed connective tissue disease.

Articles (7)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Collaborators (6)

Savino Sciascia

ITALY

View details

KAREN SALOMON-ESCOTO

Associate Professor

UMass Memorial Medical Center

UNITED STATES

View details

CHARY LOPEZ-PEDRERA

Head of Research

SPAIN

View details

Hannah Cohen

University College London Hospitals NHS Foundation Trust

UNITED KINGDOM

View details

Vittorio Pengo

Associate Professor of Cardiology

University of Padua

ITALY

View details

Andrea Fava

Johns Hopkins University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Howard Belmont

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)

A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients

Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response

Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network

Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry

Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program

Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine-treated systemic lupus erythematosus patients

Collaborators (6)

Savino Sciascia

KAREN SALOMON-ESCOTO

CHARY LOPEZ-PEDRERA

Hannah Cohen

Vittorio Pengo

Andrea Fava

Make your next move.